Pamidronic acid and cabergoline as effective long-term therapy in a 12-year-old girl with extended facial polyostotic fibrous dysplasia, prolactinoma and acromegaly in McCune-Albright syndrome: A case report

Journal of Medical Case Reports

Volumn 6, Issue , 2012, Pages

  Classen, Carl ^a   Mix, Monika ^a   Kyank, Ulrike ^a   Hauenstein, Christina ^b   Haffner, Dieter ^a,c  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b Institute for Radiology   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CABERGOLINE; GROWTH HORMONE; PAMIDRONIC ACID; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ALBRIGHT SYNDROME; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CAFE AU LAIT SPOT; CARDIOVASCULAR DISEASE; CASE REPORT; CAUCASIAN; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIPLOPIA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; ELECTROLYTE DISTURBANCE; EVOKED VISUAL RESPONSE; FACE ASYMMETRY; FACE DEFORMITY; FACIAL POLYOSTOTIC FIBROUS DYSPLASIA; FEMALE; FIBROUS DYSPLASIA; FOLLOW UP; GIGANTISM; GROWTH HORMONE BLOOD LEVEL; HEART VALVE FIBROSIS; HEMIANOPIA; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; JAW OSTEONECROSIS; KIDNEY CALCIFICATION; KIDNEY DISEASE; LUNG DISEASE; MENARCHE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROTEIN BLOOD LEVEL; PUBERTY; SCHOOL CHILD; TREATMENT DURATION; TREATMENT REFUSAL; VALVULAR HEART DISEASE;

EID: 84856071785     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-6-32     Document Type: Article

References (15)

1. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT, J Clin Endocrinol Metab 2002 87 5104 5112 10.1210/jc.2001-012022 12414879 (Pubitemid 35316352)
2. McCune-Albright syndrome-the German experience. Albers N, Jörgens S, Deiss D, Hauffa BP, J Pediatr Endocrinol Metab 2002 15 Suppl 3 897 901 12199348
3. McCune-Albright syndrome: growth hormone and prolactin hypersecretion. Christoforidis A, Maniadaki I, Stanhope R, J Pediatr Endocrinol Metab 2006 19 Suppl 2 623 625 16789626
4. Potent constitutive cyclic AMP-generating activity of XLs implicates this imprinted GNAS product in the pathogenesis of McCune-Albright syndrome and fibrous dysplasia of bone. Mariot V, Wu JY, Aydin C, Mantovani G, Mahon MJ, Linglart A, Bastepe M, Bone 2011 48 312 320 10.1016/j.bone.2010.09.032 20887824
5. McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin-case report. Almeida JP, Albuquerque LA, Ferraz CL, Mota I, Gondim J, Ferraz TM, Arq Bras Endocrinol Metabol 2009 53 102 106 10.1590/S0004-27302009000100015 19347192
6. Fibrous dysplasia of bone and McCune-Albright syndrome. Chapurlat RD, Orcel P, Best Pract Res Clin Rheumatol 2008 22 55 69 10.1016/j.berh.2007.11.004 18328981 (Pubitemid 351336924)
7. Normal vision despite narrowing of the optic canal in fibrous dysplasia. Lee JS, FitzGibbon E, Butman JA, Dufresne CR, Kushner H, Wientroub S, Robey PG, Collins MT, N Engl J Med 2002 347 1670 1676 10.1056/NEJMoa020742 12444181 (Pubitemid 35340785)
8. McCune-Albright syndrome and disorders due to activating mutations of GNAS1. Diaz A, Danon M, Crawford J, J Pediatr Endocrinol Metab 2007 20 853 880 10.1515/JPEM.2007.20.8.853 17937059 (Pubitemid 47455346)
9. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia. Isaia GC, Lala R, Defilippi C, Matarazzo P, Andreo M, Roggia C, Priolo G, de Sanctis C, Calcif Tissue Int 2002 71 121 128 10.1007/s00223-001-1098-7 12200645 (Pubitemid 36935476)
10. Use of bisphosphonates in children and adolescents. Allgrove J, J Pediatr Endocrinol Metab 2002 15 Suppl 3 921 928 12199351
11. Bisphosphonates and osteonecrosis of the jaws. Mariotti A, J Dent Educ 2008 72 919 929 18676801
12. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. Tajima T, Tsubaki J, Ishizu K, Jo W, Ishi N, Fujieda K, Endocr J 2008 55 595 599 10.1507/endocrj.K07E-042 18445999 (Pubitemid 351949758)
13. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood. Chan B, Zacharin M, J Pediatr Endocrinol Metab 2006 19 75 80 10.1515/JPEM.2006.19.1.75 16509531 (Pubitemid 43257423)
14. Pharmacological management of acromegaly: a current perspective. Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR, Neurosurg Focus 2010 29 14 20887124
15. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Gu H, Luck S, Carroll PV, Powrie J, Chambers J, Clin Endocrinol (Oxf) 2010 74 5 608 610